Trevi Therapeutics, Inc.
corporate_fare Company Profile
Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for TRVI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for TRVI spans 8-K, 10-Q, DEF 14A, 424B5.
Recent high-impact activity:
- Trevi Posts Wider Q3 Loss, $299.4M Cash Runway Into 2030, ILD Phase 2 Set for Q1 2027
- Trevi Therapeutics Q2 2026: $318.9M Cash and Phase 3 IPF Cough Trial Underway
- Stockholders Approve Doubling Authorized Shares and Expanding Stock Incentive Plan
- Trevi Therapeutics Secures $162M in April Offering, Extends Cash Runway into 2030
- Trevi Raises $162M, Extends Cash Runway to 2030, Accelerating Haduvio Phase 3 Trials
Financial Snapshot
Short Interest & Short Volume
10.13 days to coverFINRA reported short interest of 16,855,987 shares in TRVI as of the October 30, 2026 settlement, a 5.3% increase from the prior period — about 10.1 days to cover at its recent average daily volume. On November 20, 2026, 27.6% of TRVI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.